Brahmajee Kartik Nallamothu, MD, MPH
November 4th, 2009
Darbepoetin—Trick or Treat? Part I
martingallagher and Brahmajee Kartik Nallamothu, MD, MPH
(SEE PART II OF SERIES) When the FDA approved the use of recombinant erythropoietin for patients with renal disease in 1989 it was based upon the ability of this agent to reduce the need for blood transfusion, increase patient’s exercise tolerance and improve quality of life. At the time, the perceived risk of blood transfusion […]
NEJM Journal Watch — Recent Cardiology Articles- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension
- Preventive PCI of Vulnerable Plaques Linked to Fewer Cardiac Events